The success of GLP-1 receptor agonists (semaglutide, tirzepatide) has transformed the weight management landscape. But the next wave of peptide-based approaches targets different — and potentially complementary — pathways. Cagrilintide, a long-acting amylin analog, represents one of the most promising next-generation compounds in this space.
What Is Cagrilintide?
Cagrilintide is a long-acting analog of amylin, a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells after meals. While insulin manages blood glucose by promoting cellular uptake, amylin addresses the other side of the equation — it regulates how much glucose enters the bloodstream in the first place, and it communicates satiety signals to the brain.[1]
Natural amylin has a half-life of only 15-20 minutes, making it impractical as a therapeutic agent. Cagrilintide was engineered by Novo Nordisk with modifications that extend its half-life to approximately one week, enabling once-weekly subcutaneous injection.[2]
How Amylin Regulates Body Weight
Gastric Emptying: Amylin slows the rate at which food leaves the stomach, which reduces postprandial glucose spikes and extends the sensation of fullness after meals. This is a distinct mechanism from GLP-1, which also slows gastric emptying but through different receptor pathways.[1]
Central Satiety Signaling: Amylin acts on the area postrema in the brainstem — a region that regulates appetite and satiety. By activating amylin receptors in this area, cagrilintide reduces appetite and food intake through central nervous system signaling that is independent of the GLP-1 pathway.[3]
Glucagon Suppression: Amylin suppresses postprandial glucagon secretion, reducing the liver’s output of glucose after meals. This contributes to improved glycemic control and reduced insulin demand.[1]
Clinical Trial Results
Phase II clinical trials of cagrilintide have demonstrated significant weight loss in individuals with overweight and obesity. In a 26-week dose-ranging study, the highest dose of cagrilintide produced mean body weight reductions of approximately 10.8% — comparable to early semaglutide results at similar timepoints.[2]
Perhaps more significantly, Novo Nordisk is developing CagriSema — a combination of cagrilintide and semaglutide — which targets both the amylin and GLP-1 pathways simultaneously. Early Phase II data showed that the combination produced approximately 15.6% body weight loss at 32 weeks — exceeding the results of either agent alone, suggesting genuine synergy between the two pathways.[4]
Cagrilintide vs. GLP-1 Agonists
Cagrilintide and GLP-1 agonists like semaglutide are not competitors — they’re complementary. They target different receptor systems (amylin vs. GLP-1), act on overlapping but distinct brain regions, use different downstream signaling pathways to reduce appetite, and when combined, appear to produce additive or synergistic weight loss.
This is why the combination approach (CagriSema) is generating such excitement — it may represent a more comprehensive approach to weight management than targeting either pathway alone.
References
- Hay DL, et al. “Amylin: pharmacology, physiology, and clinical potential.” Pharmacological Reviews. 2015;67(3):564-600.
- Enebo LB, et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management.” The Lancet. 2021;397(10286):1736-1748.
- Lutz TA. “Control of energy homeostasis by amylin.” Cellular and Molecular Life Sciences. 2012;69(12):1947-1965.
- Frias JP, et al. “Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes.” The Lancet. 2023;402(10403):720-730.
